Display options
Cite
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016;5(1):29-51
Lauterbach, E. C. (2016). Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. American journal of neurodegenerative disease, 5(1), 29-51.
Lauterbach, Edward C. "Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease." American journal of neurodegenerative disease vol. 5,1 (2016): 29-51.
Lauterbach EC. Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease. Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016. PMID: 27073741; PMCID: PMC4788730.
Copy Download .nbib Format: NLM
Share it on

Am J Neurodegener Dis. 2016 Mar 01;5(1):29-51. eCollection 2016.

Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's disease.

American journal of neurodegenerative disease

Edward C Lauterbach

Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Mercer University School of Medicine 655 First Street, Macon, Georgia, 31201, USA.

PMID: 27073741 PMCID: PMC4788730

Abstract

Anxiety is common in the Mild Cognitive Impairment (MCI) stage of Alzheimer's disease (AD) and the pre-motor stages of Parkinson's disease (PD). A concomitant and possible cause of this anxiety is microglial activation, also considered a key promoter of neurodegeneration in MCI and early PD via inflammatory mechanisms and the generation of degenerative proinflammatory cytokines. Psychiatric disorders, prevalent in AD and PD, are often treated with psychiatric drugs (psychotropics), raising the question of whether psychotropics might therapeutically affect microglial activation, MCI, and PD. The literature of common psychotropics used in treating psychiatric disorders was reviewed for preclinical and clinical findings regarding microglial activation. Findings potentially compatible with reduced microglial activation or reduced microglial inflammogen release were evident for: antipsychotics including neuroleptics (chlorpromazine, thioridazine, loxapine) and atypicals (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone); mood stabilizers (carbamazepine, valproate, lithium); antidepressants including tricyclics (amitriptyline, clomipramine, imipramine, nortriptyline), SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), venlafaxine, and bupropion; benzodiazepine anxiolytics (clonazepam, diazepam); cognitive enhancers (donepezil, galantamine, memantine); and other drugs (dextromethorphan, quinidine, amantadine). In contrast, pramipexole and methylphenidate might promote microglial activation. The most promising replicated findings of reduced microglial activation are for quetiapine, valproate, lithium, fluoxetine, donepezil, and memantine but further study is needed and translation of their microglial effects to human disease still requires investigation. In AD-relevant models, risperidone, valproate, lithium, fluoxetine, bupropion, donepezil, and memantine have therapeutic microglial effects in need of replication. Limited clinical data suggest some support for lithium and donepezil in reducing MCI progression, but other drugs have not been studied. In PD-relevant models, lamotrigine, valproate, fluoxetine, dextromethorphan, and amantadine have therapeutic microglial effects whereas methylphenidate induced microglial activation and pramipexole promoted NO release. Clinical data limited to pramipexole do not as of yet indicate faster progression of early PD while the other drugs remain to be investigated. These tantalizing psychotropic neuroprotective findings now invite replication and evidence in AD-and PD-specific models under chronic administration, followed by consideration for clinical trials in MCI and early stage PD. Psychiatric features in early disease may provide opportunities for clinical studies that also employ microglial PET biomarkers.

Keywords: Alzheimer’s disease; Microglia; Parkinson’s disease; antidepressant; antipsychotic; anxiety; anxiolytic; cytokine; mild cognitive impairment; mood stabilizer

References

  1. J Neurosci Res. 2013 May;91(5):694-705 - PubMed
  2. J Neurosci. 2005 Mar 9;25(10):2566-75 - PubMed
  3. Neuroscience. 2014 Sep 5;275:296-304 - PubMed
  4. Brain Behav Immun. 2010 Oct;24(7):1074-7 - PubMed
  5. Front Aging Neurosci. 2010 May 21;2:null - PubMed
  6. Neurology. 2007 May 8;68(19):1596-602 - PubMed
  7. Neurochem Res. 2010 Apr;35(4):651-9 - PubMed
  8. J Geriatr Psychiatry Neurol. 2012 Dec;25(4):233-9 - PubMed
  9. Neuropharmacology. 2011 Sep;61(4):574-82 - PubMed
  10. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:207-14 - PubMed
  11. Mol Neurobiol. 2015 Feb;51(1):300-12 - PubMed
  12. Neurology. 2003 Sep 9;61(5):686-9 - PubMed
  13. Neuropathol Appl Neurobiol. 2016 Aug;42(5):423-35 - PubMed
  14. Toxicol In Vitro. 1994 Oct;8(5):1015-20 - PubMed
  15. J Pharmacol Sci. 2012;120(2):63-9 - PubMed
  16. J Neurosci. 2014 Feb 12;34(7):2583-91 - PubMed
  17. Mov Disord. 2015 Oct;30(12):1600-11 - PubMed
  18. Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):1-7 - PubMed
  19. Neurology. 2009 Jun 16;72(24):2115-21 - PubMed
  20. Brain Behav Immun. 2014 May;38:237-48 - PubMed
  21. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):42-8 - PubMed
  22. Neurobiol Dis. 2003 Dec;14 (3):417-24 - PubMed
  23. Behav Brain Res. 2016 Jan 15;297:112-5 - PubMed
  24. J Geriatr Psychiatry Neurol. 2013 Mar;26(1):34-40 - PubMed
  25. J Neurol. 2013 Nov;260(11):2849-55 - PubMed
  26. Mini Rev Med Chem. 2011 Jun;11(7):575-81 - PubMed
  27. Dement Geriatr Cogn Dis Extra. 2013 May 18;3(1):168-78 - PubMed
  28. Neurosci Lett. 2006 Apr 24;397(3):185-9 - PubMed
  29. Mov Disord. 2014 Mar;29(3):351-9 - PubMed
  30. Brain Res. 2010 Dec 2;1363:143-50 - PubMed
  31. J Parkinsons Dis. 2015;5(4):681-97 - PubMed
  32. Expert Rev Clin Pharmacol. 2014 Mar;7(2):161-5 - PubMed
  33. JAMA. 2000 Oct 18;284(15):1931-8 - PubMed
  34. Mov Disord. 2011 Feb 15;26(3):484-92 - PubMed
  35. Exp Eye Res. 2015 Jun;135:47-58 - PubMed
  36. Neurobiol Aging. 2013 Jan;34(1):128-36 - PubMed
  37. Alzheimers Dement. 2015 Jun;11(6):608-21.e7 - PubMed
  38. Exp Neurol. 2013 Mar;241:148-55 - PubMed
  39. Evid Based Med. 2013 Oct;18(5):e50 - PubMed
  40. J Neuropathol Exp Neurol. 2001 Jun;60(6):647-57 - PubMed
  41. Brain Res Bull. 2004 Aug 30;64(2):165-70 - PubMed
  42. Parkinsons Dis. 2012;2012:753548 - PubMed
  43. Epilepsia. 2014 Jan;55(1):184-92 - PubMed
  44. PLoS One. 2012;7(8):e42746 - PubMed
  45. Neurobiol Dis. 2011 Oct;44(1):63-72 - PubMed
  46. Neurotoxicology. 2014 Jan;40:23-32 - PubMed
  47. JAMA. 2002 Apr 3;287(13):1653-61 - PubMed
  48. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:236-9 - PubMed
  49. J Neurol. 2012 Jan;259(1):124-31 - PubMed
  50. Mol Cell Neurosci. 2013 Sep;56:365-74 - PubMed
  51. Iran Biomed J. 2012;16(2):90-100 - PubMed
  52. Exp Neurol. 2007 Jul;206(1):33-42 - PubMed
  53. Neuroscience. 2015 May 21;294:60-8 - PubMed
  54. Neuropsychiatr Dis Treat. 2015 Jan 30;11:243-56 - PubMed
  55. Neuroreport. 1998 Sep 14;9(13):3029-32 - PubMed
  56. J Neuroimmunol. 2009 Feb 15;207(1-2):24-31 - PubMed
  57. Eur J Pharmacol. 2015 Oct 15;765:249-57 - PubMed
  58. Eur J Pain. 2015 Jan;19(1):111-22 - PubMed
  59. Neurodegener Dis. 2010;7(1-3):38-41 - PubMed
  60. Neuroscience. 2006 Jul 21;140(4):1149-56 - PubMed
  61. J Pharmacol Exp Ther. 2007 Jun;321(3):892-901 - PubMed
  62. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30 - PubMed
  63. Anesthesiology. 2009 Jun;110(6):1379-89 - PubMed
  64. J Neuropsychiatry Clin Neurosci. 2011 Summer;23(3):242-60 - PubMed
  65. J Neurochem. 2008 Jul;106(2):815-25 - PubMed
  66. Neuropsychopharmacology. 2011 Mar;36(4):857-70 - PubMed
  67. J Pharmacol Sci. 2015 Jan;127(1):145-9 - PubMed
  68. Ann Clin Transl Neurol. 2014 Jul;1(7):512-8 - PubMed
  69. J Neurochem. 2008 Sep;106(6):2449-62 - PubMed
  70. J Pharmacol Exp Ther. 2003 Apr;305(1):212-8 - PubMed
  71. Eur J Pharmacol. 2015 May 15;755:74-9 - PubMed
  72. J Neuroinflammation. 2015 May 29;12 :108 - PubMed
  73. Dement Geriatr Cogn Disord. 2013;35(1-2):1-22 - PubMed
  74. Eur J Pharmacol. 2014 Sep 5;738:256-62 - PubMed
  75. Int J Mol Sci. 2013 Nov 15;14(11):22558-603 - PubMed
  76. Neurology. 2009 Jan 6;72 (1):56-62 - PubMed
  77. PLoS One. 2012;7(3):e33693 - PubMed
  78. Brain Behav Immun. 2012 Feb;26(2):277-83 - PubMed
  79. Neurobiol Aging. 2012 Jul;33(7):1329-42 - PubMed
  80. JAMA Psychiatry. 2015 Mar;72(3):284-91 - PubMed
  81. Mov Disord. 2011 Feb 15;26(3):436-41 - PubMed
  82. Neuropharmacology. 2011 Sep;61(4):592-9 - PubMed
  83. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1523-8 - PubMed
  84. Schizophr Res. 2013 Dec;151(1-3):20-8 - PubMed
  85. Curr Neurol Neurosci Rep. 2013 Dec;13(12 ):405 - PubMed
  86. Psychiatr Genet. 2015 Apr;25(2):71-8 - PubMed
  87. Int J Neuropsychopharmacol. 2008 Feb;11(1):111-7 - PubMed
  88. Neurology. 2015 Jun 16;84(24):2422-9 - PubMed
  89. Mol Psychiatry. 2010 Mar;15(3):272-85, 228 - PubMed
  90. Am J Geriatr Psychiatry. 2014 Dec;22(12):1418-26 - PubMed
  91. Stroke. 2003 May;34(5):1287-92 - PubMed
  92. Neurology. 2009 May 5;72(18):1555-61 - PubMed
  93. Neurosci Lett. 2010 Sep 20;482(1):51-6 - PubMed
  94. J Pharm Pharmacol. 2011 Aug;63(8):1063-9 - PubMed
  95. Int J Geriatr Psychiatry. 2009 Dec;24(12):1335-42 - PubMed
  96. Neurologist. 2007 Sep;13(5):272-93 - PubMed
  97. Intern Med. 2013;52(5):539-45 - PubMed
  98. J Neuropathol Exp Neurol. 2004 Jan;63(1):43-52 - PubMed
  99. Neurochem Int. 2012 Oct;61(5):666-71 - PubMed
  100. Int J Neuropsychopharmacol. 2006 Feb;9(1):27-35 - PubMed
  101. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Dec;29(12):1251-3 - PubMed
  102. Int J Geriatr Psychiatry. 2011 Feb;26(2):166-72 - PubMed
  103. Brain Res Mol Brain Res. 2005 Mar 24;134(1):162-9 - PubMed
  104. Support Care Cancer. 2015 Apr;23(4):953-65 - PubMed
  105. Arch Neurol. 2004 Jul;61(7):1044-53 - PubMed
  106. Neuroscience. 2015 Apr 2;290:530-42 - PubMed
  107. Neuroscience. 2006 Nov 3;142(4):1303-15 - PubMed
  108. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1306-16 - PubMed
  109. Eur Neuropsychopharmacol. 2015 Nov;25(11):2098-107 - PubMed
  110. Curr Top Med Chem. 2013;13(18):2306-27 - PubMed
  111. FASEB J. 2005 Apr;19(6):533-42 - PubMed
  112. Brain Res. 2011 Jul 27;1403:1-11 - PubMed
  113. J Neurosci. 2011 Apr 27;31(17):6277-88 - PubMed
  114. Exp Gerontol. 2015 Aug;68:51-8 - PubMed
  115. Alzheimers Dement. 2015 Sep;11(9):1041-9 - PubMed
  116. Behav Brain Res. 2012 Jan 1;226(1):351-6 - PubMed
  117. Neuroreport. 2008 Jul 2;19(10 ):997-1002 - PubMed
  118. J Alzheimers Dis. 2010;19(1):355-61 - PubMed
  119. Pharm Biol. 2014 Nov;52(11):1451-9 - PubMed
  120. Brain Behav Immun. 2016 Jul;55:225-35 - PubMed
  121. Neurology. 2004 Aug 24;63(4):651-7 - PubMed
  122. Alzheimers Dement. 2011 May;7(3):270-9 - PubMed
  123. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):107-15 - PubMed
  124. Glia. 2016 Jan;64(1):76-89 - PubMed
  125. Ann Neurol. 2005 Feb;57(2):168-75 - PubMed
  126. Am J Geriatr Psychiatry. 2015 May;23 (5):466-76 - PubMed
  127. Neurosci Res. 2013 Sep-Oct;77(1-2):87-96 - PubMed
  128. Schizophr Res. 2008 Dec;106(2-3):182-91 - PubMed
  129. Mov Disord. 2006 Jan;21(1):89-93 - PubMed
  130. Br J Psychiatry. 2011 May;198(5):351-6 - PubMed
  131. J Neuroinflammation. 2014 Mar 12;11:47 - PubMed
  132. J Neurotrauma. 2015 May 1;32(9):633-44 - PubMed
  133. Biochem Soc Trans. 2011 Aug;39(4):886-90 - PubMed
  134. PLoS One. 2014 Apr 04;9(4):e93966 - PubMed
  135. Schizophr Res. 2007 May;92(1-3):108-15 - PubMed
  136. BMC Neurol. 2012 Jun 21;12:44 - PubMed
  137. Acta Neurol Scand Suppl. 2006;185:107-14 - PubMed
  138. N Engl J Med. 2005 Jun 9;352(23):2379-88 - PubMed
  139. Neuropharmacology. 2008 Oct;55(5):826-34 - PubMed
  140. Exp Neurol. 1996 Feb;137(2):234-41 - PubMed
  141. Lancet Neurol. 2013 Aug;12 (8):747-55 - PubMed
  142. J Neuroimmune Pharmacol. 2014 Sep;9(4):582-90 - PubMed
  143. Psychol Med. 2013 May;43(5):911-20 - PubMed
  144. J Cereb Blood Flow Metab. 2015 Nov;35(11):1804-11 - PubMed
  145. Brain Behav Immun. 2016 Jul;55:151-65 - PubMed
  146. J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):8-18 - PubMed
  147. Alzheimers Dement. 2011 May;7(3):280-92 - PubMed
  148. Ann Transl Med. 2015 Jun;3(10):136 - PubMed
  149. Neuropharmacology. 2015 Aug;95:332-42 - PubMed
  150. Neurobiol Dis. 2006 Feb;21(2):404-12 - PubMed
  151. PLoS One. 2015 Mar 23;10(3):e0119768 - PubMed
  152. Int J Geriatr Psychiatry. 2011 Oct;26(10):1080-8 - PubMed
  153. Neurobiol Aging. 2011 Dec;32(12 ):2318.e31-41 - PubMed
  154. J Neuropsychiatry Clin Neurosci. 2010 Spring;22(2):130-54 - PubMed

Publication Types